10 patents
Utility
Methods for Synthesis of CHK1 Inhibitors
18 May 23
The present technology relates to processes, compounds, compositions, and methods useful for coupling reactions.
Michael SCHWAEBE, Thorsten ROSNER, Dalian ZHAO, Ross MILLER, Rich DULINA, Michael HUMORA, Stephen E. GOTTSCHLING
Filed: 6 Apr 21
Utility
Methods of Using Momelotinib to Treat Joint Inflammation
16 Mar 23
The disclosure provides methods of treating joint inflammation, including rheumatoid arthritis, in a subject using mo-melotinib (MMB).
Igor THEURL, Ryan James HANSEN, Christian Andrew HASSIG
Filed: 28 Jan 21
Utility
Phenyl Amino Pyrimidine Compounds and Uses Thereof
8 Dec 22
The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases.
Christopher John Burns, Andrew Craig Donohue, John Thomas Feutrill, Thao Lien Thi Nguyen, Andrew Frederick Wilks, Jun Zeng
Filed: 20 Apr 22
Utility
Methods of Treating Cancer Using CHK1 Inhibitors
21 Jul 22
This disclosure provides methods of using a checkpoint kinase 1 (Chk1) inhibitor in the treatment of cancer in a subject having at least an intermediate tumor mutational burden (TMB), or a genetic abnormality in one or more particular genes associated with replicative stress.
Christian Andrew Hassig, Bryan William Strouse, Ryan James Hansen, Kenna Lynn Anderes, Snezana Milutinovic, Angie J. You, Barbara Jane Klencke, Mark Kowalski
Filed: 13 May 20
Utility
Methods of Treating Cancer with Chk1 Inhibitors
16 Jun 22
Disclosed herein are methods of treatment by administering SRA737 as a monotherapy or in a combination therapy that is useful for treating patients with cancer.
Christian Andrew Hassig, Snezana Milutinovic, Ryan James Hansen, Bryan William Strouse, Lauren Byers, Triparna Sen
Filed: 26 Mar 20
Utility
Methods of Treatment of Cancer Comprising CDC7 Inhibitors
23 Dec 21
Herein disclosed are methods of treatment administering SRA141 as a monotherapy or in a combination therapy useful for inhibiting the growth of tumors such as those in patients with cancer.
Christian Andrew Hassig, Ryan James Hansen, Snezana Milutinovic, Bryan William Strouse
Filed: 28 Aug 19
Utility
Platelet Count-Agnostic Methods of Treating Myelofibrosis
30 Sep 21
Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy.
Barbara Jane Klencke, Gregg David Smith, Rafe Michael Joseph Donahue
Filed: 21 Aug 19
Utility
CHK1 (SRA737)/PARPI Combination Methods of Inhibiting Tumor Growth
18 Mar 21
Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer.
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES
Filed: 10 Apr 18
Utility
Methods of Treatment of Cancer Comprising CHK1 Inhibitors
23 Dec 20
Herein disclosed are methods of treatment administering SRA737 as a monotherapy or in a combination therapy useful for treating patients with cancer.
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES, Snezana MILUTINOVIC, Angie J. YOU, Barbara KLENCKE, Mark KOWALSKI
Filed: 25 Feb 19
Utility
Biomarkers and Patient Selection Strategies
20 May 20
Herein disclosed are methods for treatment of cancer and methods for patient selection for administration of cancer treatment regimens comprising inhibitors of checkpoint kinase 1 (Chk1).
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Angie J. YOU
Filed: 31 May 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first